AR and prostate cancer: One study has evaluated the whole blood-circulating androgen receptor (AR) transcripts of full length (AR-FL) and one of AR-Vs (AR-V1) can serve as blood-based biomarkers for identification of the primary resistance to AA in castration-resistant prostate cancer patients (10).